{"doi":"10.1056/nejmoa031681","title":"Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea","abstract":null,"journal":"New England Journal of Medicine","year":2004,"id":591723,"datarank":18.367672688145333,"base_score":6.914730892718563,"endowment":6.914730892718563,"self_citation_contribution":1.0372096339077845,"citation_network_contribution":17.330463054237548,"self_endowment_contribution":1.0372096339077845,"citer_contribution":17.330463054237548,"corpus_percentile":null,"corpus_rank":null,"citation_count":1006,"citer_count":200,"citers_with_citation_signal":200,"citers_with_endowment":200,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1513963,"name":"André Scholer","orcid":null,"position":1,"is_corresponding":false},{"id":1513964,"name":"Kirsten Laule-Kilian","orcid":null,"position":2,"is_corresponding":false},{"id":1513965,"name":"Benedict Martina","orcid":null,"position":3,"is_corresponding":false},{"id":613757,"name":"Christian Schindler","orcid":"0000-0003-3059-7613","position":4,"is_corresponding":false},{"id":1513968,"name":"Peter Buser","orcid":null,"position":5,"is_corresponding":false},{"id":1513970,"name":"Matthias Pfisterer","orcid":null,"position":6,"is_corresponding":false},{"id":1513972,"name":"André P. Perruchoud","orcid":null,"position":7,"is_corresponding":false},{"id":279167,"name":"Christian Mueller","orcid":"0000-0003-3589-8749","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea","abstract":"<h4>Background</h4>B-type natriuretic peptide levels are higher in patients with congestive heart failure than in patients with dyspnea from other causes.<h4>Methods</h4>We conducted a prospective, randomized, controlled study of 452 patients who presented to the emergency department with acute dyspnea: 225 patients were randomly assigned to a diagnostic strategy involving the measurement of B-type natriuretic peptide levels with the use of a rapid bedside assay, and 227 were assessed in a standard manner. The time to discharge and the total cost of treatment were the primary end points.<h4>Results</h4>Base-line demographic and clinical characteristics were well matched between the two groups. The use of B-type natriuretic peptide levels reduced the need for hospitalization and intensive care; 75 percent of patients in the B-type natriuretic peptide group were hospitalized, as compared with 85 percent of patients in the control group (P=0.008), and 15 percent of those in the B-type natriuretic peptide group required intensive care, as compared with 24 percent of those in the control group (P=0.01). The median time to discharge was 8.0 days in the B-type natriuretic peptide group and 11.0 days in the control group (P=0.001). The mean total cost of treatment was 5,410 dollars (95 percent confidence interval, 4,516 dollars to 6,304 dollars) in the B-type natriuretic peptide group, as compared with 7,264 dollars (95 percent confidence interval, 6,301 dollars to 8,227 dollars) in the control group (P=0.006). The respective 30-day mortality rates were 10 percent and 12 percent (P=0.45).<h4>Conclusions</h4>Used in conjunction with other clinical information, rapid measurement of B-type natriuretic peptide in the emergency department improved the evaluation and treatment of patients with acute dyspnea and thereby reduced the time to discharge and the total cost of treatment.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"14960741","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa031681","host_type":"publisher"}],"fields_of_study":[],"mesh_terms":["Humans","Dyspnea","Acute Disease","Natriuretic Peptide, Brain","Hospitalization","Length of Stay","Prospective Studies","Single-Blind Method","Adult","Aged","Aged, 80 and over","Middle Aged","Emergency Service, Hospital","Hospital Costs","Female","Male","Heart Failure","Biomarkers"],"keywords":[],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-26T10:23:54.359474Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}